Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Debt to Equity (2021 - 2024)

Standard Biotools has reported Debt to Equity over the past 7 years, most recently at $0.11 for Q3 2024.

  • Quarterly Debt to Equity rose 253.74% to $0.11 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $0.11 through Sep 2024, up 253.74% year-over-year, with the annual reading at -$0.39 for FY2023, 289.12% down from the prior year.
  • Debt to Equity was $0.11 for Q3 2024 at Standard Biotools, up from $0.11 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.46 in Q1 2022 and troughed at -$0.39 in Q4 2023.
  • The 4-year median for Debt to Equity is -$0.08 (2023), against an average of -$0.03.
  • Year-over-year, Debt to Equity plummeted 289.12% in 2023 and then skyrocketed 253.74% in 2024.
  • A 4-year view of Debt to Equity shows it stood at $0.11 in 2021, then plummeted by 194.68% to -$0.1 in 2022, then plummeted by 289.12% to -$0.39 in 2023, then skyrocketed by 128.67% to $0.11 in 2024.
  • Per Business Quant, the three most recent readings for LAB's Debt to Equity are $0.11 (Q3 2024), $0.11 (Q2 2024), and -$0.39 (Q4 2023).